Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Moehler

Showing results (191-200 of 218) with videos related to

Pageof 22
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 2, 2022
Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancerTiuri E Kroese, Peter S N van Rossum, Magnus Nilsson, et al.
International Journal of Cancer|October 20, 2017
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trialJulian Walter Holch, Ingrid Ricard, Sebastian Stintzing, et al.
Nature|March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancerKohei Shitara, Jaffer A Ajani, Markus Moehler, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2012
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancerManfred P Lutz, John R Zalcberg, Michel Ducreux, et al.
Future Oncology (London, England)|June 17, 2024
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancerLipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, et al.
JAMA Oncology|April 28, 2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 TrialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
The New England Journal of Medicine|June 2, 2025
Perioperative Durvalumab in Gastric and Gastroesophageal Junction CancerYelena Y Janjigian, Salah-Eddin Al-Batran, Zev A Wainberg, et al.
Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2016
Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24]Manfred P Lutz, John R Zalcberg, Rob Glynne-Jones, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2016
Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancerManfred P Lutz, John R Zalcberg, Rob Glynne-Jones, et al.
Pageof 22

Showing results (191-200 of 218) with videos related to

Sort By:
Pageof 22
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 2, 2022
Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancerTiuri E Kroese, Peter S N van Rossum, Magnus Nilsson, et al.
International Journal of Cancer|October 20, 2017
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trialJulian Walter Holch, Ingrid Ricard, Sebastian Stintzing, et al.
Nature|March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancerKohei Shitara, Jaffer A Ajani, Markus Moehler, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2012
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancerManfred P Lutz, John R Zalcberg, Michel Ducreux, et al.
Future Oncology (London, England)|June 17, 2024
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancerLipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, et al.
JAMA Oncology|April 28, 2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 TrialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
The New England Journal of Medicine|June 2, 2025
Perioperative Durvalumab in Gastric and Gastroesophageal Junction CancerYelena Y Janjigian, Salah-Eddin Al-Batran, Zev A Wainberg, et al.
Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2016
Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24]Manfred P Lutz, John R Zalcberg, Rob Glynne-Jones, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2016
Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancerManfred P Lutz, John R Zalcberg, Rob Glynne-Jones, et al.
Pageof 22